Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Ming Chih Chang"'
Autor:
Chi Wang, Nai-Wen Su, Kate Hsu, Chen-Wei Kao, Ming-Chih Chang, Yi-Fang Chang, Ken-Hong Lim, Yi-Hao Chiang, Yu-Cheng Chang, Meng-Ta Sung, Hsueh-Hsia Wu, Caleb G. Chen
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-13 (2024)
Abstract Background Despite the advances of therapies, multiple myeloma (MM) remains an incurable hematological cancer that most patients experience relapse. Tumor angiogenesis is strongly correlated with cancer relapse. Human leukocyte antigen G (HL
Externí odkaz:
https://doaj.org/article/68855d57d6044c93889ec0390a9f0a6d
Autor:
Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Po-Nan Wang, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu
Publikováno v:
PLoS ONE, Vol 19, Iss 8 (2024)
Externí odkaz:
https://doaj.org/article/a24dce73854148dc9828f7489ea2bfaa
Autor:
Yu-Cheng Chang, Yi-Hao Chiang, Kate Hsu, Chih-Kuang Chuang, Chen-Wei Kao, Yi-Fang Chang, Ming-Chih Chang, Ken-Hong Lim, Hung-I Cheng, Yen-Ning Hsu, Caleb G. Chen
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-10 (2021)
Abstract Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (γδT) cells possess the potent anticancer
Externí odkaz:
https://doaj.org/article/9de7eaa081b649b584d078d1f35041b7
Publikováno v:
Maxillofacial Plastic and Reconstructive Surgery, Vol 39, Iss 1, Pp 1-5 (2017)
Abstract Background Rehabilitation of normal function and form is essential in cleft lip repair. In 2005, Dr. David M. Fisher introduced an innovative method, named “an anatomical subunit approximation technique” in unilateral cleft lip repair. A
Externí odkaz:
https://doaj.org/article/c3b422e0a06c463db288daa40ae69b45
Autor:
Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang
Publikováno v:
Oncology Reviews, Vol 13, Iss 1 (2019)
Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in
Externí odkaz:
https://doaj.org/article/1d2c495198cc4729af7bf7c8c4354a95
Autor:
Wen-Li Hwang, Tsung-Chih Chen, Hsuan-Yu Lin, Ming-Chih Chang, Pei-Ching Hsiao, Li-Yuan Bai, Ching-Yuan Kuo, Yeu-Chin Chen, Ta-Chih Liu, Jyh-Pyng Gau, Po-Nan Wang, Wei-Shou Hwang, Ming-Chung Kuo, Chun-Yu Liu, Yi-Chang Liu, Ming-Chun Ma, Nai-Wen Su, Chuan-Cheng Wang, Yi-Ying Wu, Ming Yao, Su-Peng Yeh, Hao-Wei Cheng, Yee-Ming Lee, Fan-Chen Ku, Jih-Luh Tang
Publikováno v:
International Journal of Hematology. 115:704-712
Nilotinib has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::032592d1c1e4fbff114d86c29f453108
https://doi.org/10.1007/s12185-022-03311-1
https://doi.org/10.1007/s12185-022-03311-1
Autor:
Ming-Chung Kuo, Chien-Chin Lin, Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Cih-En Huang, I-Ju Chiang, Chu-Han Chung, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang
Publikováno v:
Blood. 140:9709-9710
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a87996b007b8fe9457e6b94410c81da
https://doi.org/10.1182/blood-2022-156146
https://doi.org/10.1182/blood-2022-156146
Autor:
Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu
BackgroundCD19-targeted chimeric antigen receptor therapies (CAR19) have driven a paradigm shift in the treatment of relapsed/refractory B-cell malignancies. However, >50% of CAR19-treated patients experienced progressive disease mainly due to antige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70c7124184947136f175986840868698
https://doi.org/10.1101/2022.05.03.490475
https://doi.org/10.1101/2022.05.03.490475
Autor:
Huan-Chau Lin, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Chen Wei Kao, An-Chi Lo, Nai-Wen Su, Yu-Cheng Chang, Yi-Hao Chiang, Kuei-Fang Chou, Po-Nien Liao, Guan-Jhe Cai, Hung-I Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Ken-Hong Lim
Publikováno v:
International Journal of Gerontology, Vol 7, Iss 1, Pp 40-44 (2013)
Background: Essential thrombocythemia (ET) is classified as a chronic myeloproliferative neoplasm. JAK2 V617F mutation is found in about 50–60% patients with ET. We aim to determine the prevalence of JAK2 V617F mutation and its association with phe
Externí odkaz:
https://doaj.org/article/5f37be7a6b3a4ffc9382b114777bd644
Autor:
Caleb Gon-Shen Chen, Ming-Chih Chang, Yi-Fang Chang, Chia-Ching Chang, Ken-Hong Lim, Kate Hsu, Chia-Yu Chang, Lih-Chyang Chen, Chen-Wei Kao
Publikováno v:
Cell Death and Disease, Vol 11, Iss 9, Pp 1-13 (2020)
Cell Death & Disease
Cell Death & Disease
BAFF supports B-cell survival and homeostasis by activating the NF-κB pathway. While NF-κB is also involved in the priming signal of NLRP3 inflammasome, the role of BAFF in NLRP3 inflammasome regulation is unknown. Here we report BAFF engagement to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::383b676348444d2fe8bec54b38bf131f
http://link.springer.com/article/10.1038/s41419-020-03035-2
http://link.springer.com/article/10.1038/s41419-020-03035-2